查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1679172

乳房復發評分檢測市場：全球產業分析、規模、佔有率、成長、趨勢及預測（2025-2032）

Breast Recurrence Score Test Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 233 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

Persistence Market Research 最近發布了一份關於全球乳癌復發評分測試市場的綜合報告。該報告對市場促進因素、趨勢、機會、促進因素和挑戰等關鍵市場動態進行了全面評估，並對市場結構提供了詳細的見解。本研究報告提供獨家資料和統計數據，概述了 2025 年至 2032 年全球乳房復發評分測試市場的預期成長軌跡。

關鍵見解

  • 乳癌復發評分測試市場規模（2025年）：2.811億美元
  • 市場預測（2032 年）：5.295 億美元
  • 全球市場成長率（2025-2032年複合年成長率）：9.5%

乳癌復發評分測試市場-報告內容：

乳房復發評分測試是一種基因組檢測，用於評估早期乳癌患者癌症復發的可能性。此測試可幫助腫瘤科醫師確定是否需要化療，從而實現更個人化的治療方法。乳房復發評分測試市場的目標是醫院、診斷實驗室、研究機構和專門的腫瘤中心。市場成長的動力來自於精準醫療意識的不斷增強、乳癌發病率的上升以及基因組檢測在臨床決策中的日益普及。

市場促進因素：

全球乳房復發評分測試市場受到幾個關鍵因素的推動，例如全球乳癌發生率的增加和個人化醫療需求的增加。基因組檢測技術的進步，加上腫瘤學對分子診斷的日益接受，將進一步推動市場擴張。支持基因檢測的報銷政策以及政府推動癌症篩檢計畫的措施不斷增加也促進了市場的擴張。此外，向非侵入性、經濟高效的診斷解決方案的轉變正在推動乳房復發評分測試的採用。

市場限制：

儘管成長前景看好，但乳房復發評分測試市場仍面臨著與法規遵循、測試成本高以及新興地區認知度低相關的挑戰。基因組檢測的嚴格監管核准和各國不同的報銷政策是市場滲透的障礙。此外，乳癌復發評分測試的高成本可能會限制其在低收入國家的普及，從而抑制其應用。應對這些挑戰需要監管機構、醫療保健提供者和市場相關人員共同努力，提高測試的可負擔性和可近性。

市場機會：

由於技術進步、癌症研究投資的增加以及基因組檢測在腫瘤學中的應用不斷擴大，乳房復發評分測試市場提供了巨大的成長機會。人工智慧 (AI) 和機器學習在基因組資料解釋中的整合將提高測試準確性並支援臨床決策。此外，製藥公司和診斷公司之間為開發先進的分子檢測解決方案而建立的策略聯盟將為市場擴張開闢新的途徑。人們對早期癌症檢測的日益關注，加上政府推動精準醫療的舉措，為市場參與者提供了進一步創新和加強其影響力的機會。

本報告探討的關鍵問題

  • 推動全球乳房復發評分測試市場成長的關鍵因素有哪些？
  • 哪些醫療機構正在率先採用乳房復發評分測試？
  • 技術進步如何影響乳房復發評分測試市場的競爭格局？
  • 哪些主要企業為市場做出了貢獻？他們採取了哪些策略來維持市場相關性？
  • 全球乳房復發評分測驗市場的新興趨勢和未來前景是什麼？

目錄

第1章執行摘要

第2章 市場概述

  • 市場範圍和定義
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
    • 主要趨勢
  • 宏觀經濟因素
    • 全球產業展望
    • 全球GDP成長前景
  • COVID-19影響分析
  • 預測因子－相關性和影響力

第3章 增值洞察

  • 產品採用分析
  • 監管狀況
  • 價值鏈分析
  • PESTLE分析
  • 波特五力分析

第4章全球乳房復發評分測試市場展望

  • 主要亮點
    • 市場規模及與前一年同期比較率
    • 絕對的商機
  • 市場規模分析與預測
    • 2019-2024 年歷史市場規模分析
    • 目前市場規模分析與預測，2025-2032
  • 全球乳房復發評分測試市場展望：產品
    • 簡介/主要發現
    • 2019 年至 2024 年按產品分類的歷史市場規模分析
    • 2025 年至 2032 年按產品分類的當前市場規模分析與預測
      • 檢測套組
      • 試劑和耗材
    • 市場吸引力分析：產品
  • 全球乳房復發評分測試市場展望：適應症
    • 簡介/主要發現
    • 2019 年至 2024 年各適應症的歷史市場規模
    • 目前市場規模分析與預測（按適應症），2025 年至 2032 年
      • 乳癌1期
      • 乳癌2期
      • 雌激素受體陽性癌症
      • 淋巴結陰性癌症
    • 市場吸引力分析：跡象
  • 全球乳房復發評分測試市場展望：最終用戶
    • 簡介/主要發現
    • 2019 年至 2024 年最終用戶市場規模歷史分析
    • 2025 年至 2032 年按最終用戶分類的當前市場規模分析和預測
      • 醫院
      • 專門癌症中心
      • 診斷中心
      • 癌症研究所
    • 市場吸引力分析：最終用戶

5. 全球乳房復發評分測試市場（按地區）展望

  • 主要亮點
  • 2019 年至 2024 年各地區歷史市場規模分析
  • 2025 年至 2032 年各地區目前市場規模分析與預測
    • 北美洲
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：地區

6. 北美乳房復發評分測試市場展望

7. 歐洲乳房復發評分測試市場展望

8. 東亞乳房復發評分測試市場展望

9.南亞和大洋洲乳房復發評分測試市場展望

10.拉丁美洲乳房復發評分測試市場展望

11.中東和非洲乳房復發評分測試市場展望

第12章競爭格局

  • 2024年市場佔有率分析
  • 市場結構
    • 市場競爭加劇圖
    • 競爭儀錶板
  • 公司簡介（詳情－概述、財務狀況、策略、最新發展）
    • ThermoFisher Scientific
    • Exact Sciences（Genome Health Inc.）
    • NanoString Technologies, Inc.
    • Foundation Medicine, Inc
    • Illumina, Inc
    • Hologic Inc（Biotheranostic）
    • Biocartis
    • Roche Diagnostics
    • Epic Sciences
    • Qiagen
    • Abbott
    • Myriad Genetics, Inc
    • Guardant Health
    • Agendia
    • Genomic Health
    • iCAD
    • CancerIQ
    • Siemens Healthineers
    • General Electric Company
    • Koninklijke Philips NV

第13章 附錄

  • 調查方法
  • 調查前提
  • 首字母縮寫和簡稱
簡介目錄
Product Code: PMRREP32146

Persistence Market Research has recently released a comprehensive report on the worldwide market for Breast Recurrence Score Tests. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global Breast Recurrence Score Test Market from 2025 to 2032.

Key Insights:

  • Breast Recurrence Score Test Market Size (2025E): US$ 281.1 Mn
  • Projected Market Value (2032F): US$ 529.5 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 9.5%

Breast Recurrence Score Test Market - Report Scope:

The Breast Recurrence Score Test is a genomic assay used to assess the likelihood of cancer recurrence in patients diagnosed with early-stage breast cancer. This test aids oncologists in determining the necessity of chemotherapy, allowing for more personalized treatment approaches. The market for breast recurrence score tests caters to hospitals, diagnostic laboratories, research institutions, and specialty oncology centers. Market growth is fueled by increasing awareness of precision medicine, rising breast cancer prevalence, and the growing adoption of genomic testing in clinical decision-making.

Market Growth Drivers:

The global Breast Recurrence Score Test Market is propelled by several key factors, including the increasing incidence of breast cancer worldwide and the growing demand for personalized medicine. Advancements in genomic testing technologies, coupled with the rising acceptance of molecular diagnostics in oncology, further drive market expansion. The availability of reimbursement policies supporting genetic testing and increasing government initiatives promoting cancer screening programs also contribute to market growth. Furthermore, the shift towards non-invasive and cost-effective diagnostic solutions encourages the adoption of breast recurrence score tests.

Market Restraints:

Despite its promising growth, the Breast Recurrence Score Test Market faces challenges related to regulatory compliance, high testing costs, and limited awareness in developing regions. Stringent regulatory approvals for genomic tests and variations in reimbursement policies across different countries pose hurdles for market penetration. Additionally, the high cost associated with breast recurrence score tests may limit their accessibility in low-income countries, restricting widespread adoption. Addressing these challenges requires collaborative efforts between regulatory authorities, healthcare providers, and market players to enhance test affordability and accessibility.

Market Opportunities:

The Breast Recurrence Score Test Market presents significant growth opportunities driven by technological advancements, increased investments in cancer research, and the expanding applications of genomic testing in oncology. The integration of artificial intelligence (AI) and machine learning in genomic data interpretation enhances test accuracy and supports clinical decision-making. Furthermore, strategic partnerships between pharmaceutical companies and diagnostic firms for the development of advanced molecular testing solutions create new avenues for market expansion. The growing focus on early cancer detection, coupled with government initiatives promoting precision medicine, offers further opportunities for market players to innovate and strengthen their presence.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Breast Recurrence Score Test Market globally?
  • Which healthcare settings are leading in the adoption of breast recurrence score tests?
  • How are technological advancements shaping the competitive landscape of the Breast Recurrence Score Test Market?
  • Who are the key players contributing to the market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global Breast Recurrence Score Test Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Breast Recurrence Score Test Market, including Exact Sciences Corporation, Myriad Genetics, Inc., and Agendia Inc., focus on innovation, clinical validation, and strategic collaborations to strengthen their market presence. These companies invest in research and development to enhance the accuracy and predictive capabilities of genomic assays. Partnerships with healthcare providers, research institutions, and biotechnology firms facilitate the integration of breast recurrence score tests into clinical workflows. Additionally, efforts to expand test accessibility through reimbursement policies and awareness campaigns contribute to market growth and patient adoption.

Key Companies Profiled:

  • Exact Sciences Corporation
  • Myriad Genetics, Inc.
  • Agendia Inc.
  • BioTheranostics, Inc.
  • Genomic Health, Inc. (A subsidiary of Exact Sciences)
  • NanoString Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • Guardant Health, Inc.
  • OncoDNA S.A.
  • LabCorp (Laboratory Corporation of America)

Breast Recurrence Score Market Segmentation

Product:

  • Test Kits
  • Reagents & Consumables

Indication:

  • Stage 1 Breast Cancer
  • Stage 2 Breast Cancer
  • Estrogen-Receptor-Positive Cancer
  • Lymph-Node-Negative Cancer

End User:

  • Hospitals
  • Specialty Cancer Centers
  • Diagnostic Centers
  • Cancer Research Institutions

Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Breast Recurrence Score Test Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Value Chain Analysis
  • 3.4. PESTLE Analysis
  • 3.5. Porter's Five Force Analysis

4. Global Breast Recurrence Score Test Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Breast Recurrence Score Test Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Test Kits
      • 4.3.3.2. Reagents & Consumables
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Breast Recurrence Score Test Market Outlook: Indication
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn), By Indication, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
      • 4.4.3.1. Stage 1 Breast Cancer
      • 4.4.3.2. Stage 2 Breast Cancer
      • 4.4.3.3. Estrogen-Receptor-Positive Cancer
      • 4.4.3.4. Lymph-Node-Negative Cancer
    • 4.4.4. Market Attractiveness Analysis: Indication
  • 4.5. Global Breast Recurrence Score Test Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospitals
      • 4.5.3.2. Specialty Cancer Centers
      • 4.5.3.3. Diagnostic Centers
      • 4.5.3.4. Cancer Research Institutions
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Breast Recurrence Score Test Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Breast Recurrence Score Test Market Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Indication
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Test Kits
    • 6.4.2. Reagents & Consumables
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 6.5.1. Stage 1 Breast Cancer
    • 6.5.2. Stage 2 Breast Cancer
    • 6.5.3. Estrogen-Receptor-Positive Cancer
    • 6.5.4. Lymph-Node-Negative Cancer
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospitals
    • 6.6.2. Specialty Cancer Centers
    • 6.6.3. Diagnostic Centers
    • 6.6.4. Cancer Research Institutions
  • 6.7. Market Attractiveness Analysis

7. Europe Breast Recurrence Score Test Market Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Indication
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Test Kits
    • 7.4.2. Reagents & Consumables
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 7.5.1. Stage 1 Breast Cancer
    • 7.5.2. Stage 2 Breast Cancer
    • 7.5.3. Estrogen-Receptor-Positive Cancer
    • 7.5.4. Lymph-Node-Negative Cancer
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Specialty Cancer Centers
    • 7.6.3. Diagnostic Centers
    • 7.6.4. Cancer Research Institutions
  • 7.7. Market Attractiveness Analysis

8. East Asia Breast Recurrence Score Test Market Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Indication
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Test Kits
    • 8.4.2. Reagents & Consumables
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 8.5.1. Stage 1 Breast Cancer
    • 8.5.2. Stage 2 Breast Cancer
    • 8.5.3. Estrogen-Receptor-Positive Cancer
    • 8.5.4. Lymph-Node-Negative Cancer
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Specialty Cancer Centers
    • 8.6.3. Diagnostic Centers
    • 8.6.4. Cancer Research Institutions
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Breast Recurrence Score Test Market Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Indication
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Test Kits
    • 9.4.2. Reagents & Consumables
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 9.5.1. Stage 1 Breast Cancer
    • 9.5.2. Stage 2 Breast Cancer
    • 9.5.3. Estrogen-Receptor-Positive Cancer
    • 9.5.4. Lymph-Node-Negative Cancer
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Specialty Cancer Centers
    • 9.6.3. Diagnostic Centers
    • 9.6.4. Cancer Research Institutions
  • 9.7. Market Attractiveness Analysis

10. Latin America Breast Recurrence Score Test Market Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Indication
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Test Kits
    • 10.4.2. Reagents & Consumables
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 10.5.1. Stage 1 Breast Cancer
    • 10.5.2. Stage 2 Breast Cancer
    • 10.5.3. Estrogen-Receptor-Positive Cancer
    • 10.5.4. Lymph-Node-Negative Cancer
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Specialty Cancer Centers
    • 10.6.3. Diagnostic Centers
    • 10.6.4. Cancer Research Institutions
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Breast Recurrence Score Test Market Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Indication
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Test Kits
    • 11.4.2. Reagents & Consumables
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 11.5.1. Stage 1 Breast Cancer
    • 11.5.2. Stage 2 Breast Cancer
    • 11.5.3. Estrogen-Receptor-Positive Cancer
    • 11.5.4. Lymph-Node-Negative Cancer
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Specialty Cancer Centers
    • 11.6.3. Diagnostic Centers
    • 11.6.4. Cancer Research Institutions
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. ThermoFisher Scientific
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Exact Sciences (Genome Health Inc.)
    • 12.3.3. NanoString Technologies, Inc.
    • 12.3.4. Foundation Medicine, Inc
    • 12.3.5. Illumina, Inc
    • 12.3.6. Hologic Inc (Biotheranostic)
    • 12.3.7. Biocartis
    • 12.3.8. Roche Diagnostics
    • 12.3.9. Epic Sciences
    • 12.3.10. Qiagen
    • 12.3.11. Abbott
    • 12.3.12. Myriad Genetics, Inc
    • 12.3.13. Guardant Health
    • 12.3.14. Agendia
    • 12.3.15. Genomic Health
    • 12.3.16. iCAD
    • 12.3.17. CancerIQ
    • 12.3.18. Siemens Healthineers
    • 12.3.19. General Electric Company
    • 12.3.20. Koninklijke Philips NV

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations